Skip to main content
Clinical Trials/NCT04119739
NCT04119739
Completed
Phase 4

Pain Reduction Produced by Physiotherapy, Ibuprofen, and the Absence of Treatment, in Carpal Tunnel Syndrome

Francisco Unda Solano1 site in 1 country117 target enrollmentApril 14, 2020

Overview

Phase
Phase 4
Intervention
Median nerve neural mobilization
Conditions
Carpal Tunnel Syndrome
Sponsor
Francisco Unda Solano
Enrollment
117
Locations
1
Primary Endpoint
Distal upper limb pain
Status
Completed
Last Updated
4 months ago

Overview

Brief Summary

Pain reduction effects of the median nerve neural mobilization technique (a physiotherapy treatment) will be compared to those produced by a pharmaceutical treatment and the absence of treatment, in subjects who suffer carpal tunnel syndrome.

Detailed Description

The present randomized clinical trial will perform a comparison of the pain reduction effects produced by the application of median nerve neural mobilization (non invasive and non pharmaceutical physiotherapy treatment), to the pain reduction effect produced by an oral ibuprofen treatment or the lack of treatment (waiting list control group) in subjects diagnosed with carpal tunnel syndrome. Additionally, effects over the functionality of the affected upper limb will be evaluated and compared. Subjects will be invited to participate and randomly allocated to 3 different groups.

Registry
clinicaltrials.gov
Start Date
April 14, 2020
End Date
July 28, 2020
Last Updated
4 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Francisco Unda Solano
Responsible Party
Sponsor Investigator
Principal Investigator

Francisco Unda Solano

Biomedicine Doctorate Program Investigator

Universidad Europea de Madrid

Eligibility Criteria

Inclusion Criteria

  • Participants must be medically diagnosed with unilateral carpal tunnel syndrome (with confirmative electrodiagnostic findings).
  • Full understanding of written and spoken Spanish (language).
  • Participants must freely consent to participate.
  • The presence of positive Phalen and Tinel signs.
  • The presence of carpal tunnel syndrome signs and symptoms

Exclusion Criteria

  • The lack to meet inclusion criterions, the presence of cognitive impairment.
  • Upper limb surgery or trauma
  • Pregnancy
  • Deformities of the (affected) upper limb
  • Recent skin injuries or infections (in the affected upper limb)
  • Autoimmune inflammatory conditions or flu type symptoms.
  • Allergy to gabapentin, ibuprofen or ibuprofen arginine
  • Participants must not be (during the present investigation) under any type of pain reducing treatment (conservative, homeopathic, invasive or not invasive).
  • Metabolic neuropathy.
  • Obesity (body mass index over 30).

Arms & Interventions

Median nerve neural mobilization

Non pharmaceutical, non invasive, physiotherapy technique; which consists of a passive and repetitive upper limb movement that seeks to induced median nerve gliding and incursions against surrounding connective tissue. Subjects will be treated 5 days per week during a total time lapse of 4 weeks.

Intervention: Median nerve neural mobilization

Ibuprofen Arginine

Oral tablet pharmaceutical treatment. Participants will be treated with a maximum of 1200 mg per day, subdivided in 3 intakes of 400 mg each 8 hours during a time lapse of 4 weeks.

Intervention: Ibuprofen Arginine

Outcomes

Primary Outcomes

Distal upper limb pain

Time Frame: Changes from baseline (measured immediately before the application of the first treatment) and 40 minutes after the application of the last treatment.

Assessed through the visual analog scale (VAS). The VAS is a psychometric response scale. It is a measurement instrument for subjective characteristics or attitudes that cannot be directly measured.The VAS is the most frequently used method to assess pain intensity. The scale will be displayed as a horizontal 10-cm line labelled at each end by descriptors such as 'no pain' (the minimum and best outcome possible) and 'worse pain ever' (maximum and worst outcome possible). The participant will mark the line to indicate pain severity and it is simply quantified by measuring the distance in centimeters from 0 (no pain) to the patient's marked rating.

Secondary Outcomes

  • Upper limb function(Changes from baseline (measured immediately before the application of the first treatment) and at 40 minutes after the application of the last treatment.)

Study Sites (1)

Loading locations...

Similar Trials